Wellbutrin XL contains bupropion hydrochloride 150mg in an extended release (XL) tablet formulation. Bupropion is an antidepressant with a pharmacological profile that differs from selective serotonin reuptake inhibitors (SSRIs), as its activity is primarily associated with norepinephrine and dopamine signaling rather than serotonin reuptake inhibition. Wellbutrin XL 150mg is an approved prescription extended release tablet formulation in Canada.
Although the exact antidepressant mechanism of bupropion has not been completely established, it is considered a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine. By reducing the reuptake of these neurotransmitters, bupropion can increase noradrenergic and dopaminergic activity within pathways involved in mood, motivation, attention, and reward processing. Unlike SSRIs, bupropion does not significantly inhibit serotonin reuptake.
Bupropion XL is used primarily in the treatment of major depressive disorder (MDD). Its extended release formulation is designed to release bupropion gradually over an extended period, allowing for once daily administration when prescribed appropriately. The XL formulation is available in both 150mg and 300mg extended release tablet strengths.
Bupropion is metabolized to several pharmacologically active metabolites, including hydroxybupropion, threohydrobupropion, and erythrohydrobupropion, which contribute to overall exposure and activity. Following chronic administration, steady state concentrations are generally reached within approximately eight days, while the mean elimination half-life of bupropion is about 21 hours.
This product provides:
- Active Ingredient: Bupropion Hydrochloride
- Brand: Wellbutrin XL
- Strength: 150mg per tablet
- Quantity: 90 Tablets
- Drug Class: Antidepressant / Norepinephrine Dopamine Reuptake Inhibitor
- Dosage Form: Extended Release Tablet
- Primary Use: Major Depressive Disorder
Wellbutrin XL has several important safety considerations. One of the most significant is a dose related risk of seizures. It is contraindicated in patients with seizure disorders and in individuals with a current or previous diagnosis of bulimia or anorexia nervosa, as these conditions are associated with an increased seizure risk. Abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or certain antiepileptic medications can also increase this risk.
Bupropion can also cause increases in blood pressure or hypertension, so blood pressure monitoring may be appropriate in susceptible patients. Other commonly reported effects can include insomnia, dry mouth, headache, nausea, agitation, anxiety, dizziness, and changes in appetite.
As with other antidepressants, bupropion carries warnings regarding possible suicidal thoughts and behavioral changes in children, adolescents, and young adults, particularly during early treatment or following changes in therapy. Patients should be appropriately monitored for significant changes in mood or behavior.
Wellbutrin XL should not be taken together with other medications containing bupropion, including other Wellbutrin formulations or smoking cessation products containing the same active ingredient, unless specifically directed by a healthcare professional.
The extended release tablet should remain intact so that its controlled release characteristics are preserved. Bupropion is a prescription medication and should be used according to the directions and monitoring recommendations of a qualified healthcare professional.
